Necessity, Importance, Future Aspects and Challenges of Pharmacovigilance
Pharmacovigilance (PV) is kind of a sunshade to clarify the processes for observance and evaluating Adverse Drug Reactions (ADRs) and it’s a key part of effective drug regulation systems, clinical follow and public health programs. Spontaneous news of ADRs could be an important part of PV & it becomes a major disadvantage in developing countries. Knowledge of PV might sort the thought for interventions aimed toward up news rates and decreasing ADRs. PV could be an important and integral part of clinical analysis & it jointly plays employment among the help system through observance and interaction of medication and there effects among the body. Nowadays in state, PV provides awareness relating to ADRs and this review provides knowledge relating to implementation for determination of current problems. India’s rising stage; there is heaps to be done and told, the sphere of PV, in ensuring that the safe implementation of the activities and work done is achieved. Their increasing kind of hospitalization of patients as a results of ADRs and it becomes a challenge to hunt out the precise cause, once a patient is treated with multiple medication at a similar time. PV helps in safe and convenient use of pharmaceutical medication. The foremost objective of PV is that the assessment of benefit-risk profile of drug for higher potency and safety in patients. This review explains the need of Pharmacovigilance in companies, its growth in various centuries and current standing among the country.
2. Pirmohamed M, James S, Makin S, Green C, Scott AK, Walleye TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329(7456):15-9.
3. Basile, A. O., Yahi, A., and Tatonetti, N. P. Artificial Intelligence for Drug Toxicity and Safety. Trends Pharmacol. Sci. 2019; 40(9):624–635.
4. Geneva: World Health Organization. Looking at the Pharmacovigilance: ensuring the safe use of medicines. WHO Policy Perspectives on Medicines. Geneva: WHO; 2004. Available from: http://www.whqlibdoc.who.int/ hq/2004/WHO_EDM_2004.8.pdf. [Cited on 2009 Dec 15].
5. Harmark L, van Grootheest AC. Pharmacovigilance: Methods, recent developments and future perspectives. Eur J ClanPharmacology 2008; 64:743-52.
6. World Health Organization(WHO), Uppsala Monitoring Centre (internet). The use of WHO-UMC system for standard case causality assessment available at http://www.whoumc.org/graphics/4409.pdf.
7. Macedo AF, Marques FB, and Ribeiro CF, Teixeira F. Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. Pharmacoepidemiological drug soft. 2005; 14:885-890.
8. WHO Policy Perspectives on Medicines. Geneva: WHO; 2004. Geneva: World Health Organization. Looking at the Pharmacovigilance: ensuring the safe use of medicines.
9. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J Clin Epidemiol 1993; 46(11):1323-30.
10. Naman M Singh, K.; Kanase, H. R. Pharmacovigilance Programme of India: The Beginning, Current Status and Recent Progress. Advances in Pharmacoepidemiology and Drug Safety2017; 06 (04):4–6.
11. Sharma, B., Bhattacharya A., Gandhi, R., Jayshree Sood., Rao, B.K. „Pharmacovigilance in intensive care unit –An overview‟, Indian journal of Anesthesia, 2008; 52(4):373-384.
12. Dylan Fernandes, S., Anoop, N. V., Castelino, L. J., & Narayana Charyulu, R. (2019). A national approach to Pharmacovigilance: The case of India as a growing hub of global clinical trials. Research in social & administrative pharmacy: RSAP, 2019; 15(1):109–113.
13. Lazarou J, Pomeranz BH, Corey PN; Incidence of Adverse Drug Reactions in hospitalized patients. JAMA, 1998; 279: 1200-1205
14. Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D. Underreporting in Pharmacovigilance: An intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol 2013; 69:237-44.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).